

# Updates in Hematology & Hematologic Malignancies

Friday, April 11, 2025 8am-4pm

The Omni Charlottesville Hotel, 212 Ridge McIntire Road  
Charlottesville, VA

Provided by the University of Virginia School of Medicine  
and the School of Nursing



## Agenda

7:00-8:00

**Registration, Breakfast and Exhibits**

8:00-8:05

**Welcome/Program Overview**  
Hillary Maitland, MD, MS

**8:05-9:25**

**Lymphoid Malignancy**

8:05-8:30

**Lymphoid Malignancy**  
Nathan Roberts, MD

8:30-9:15

**How I treat CLL in 2025**  
Matthew Davids, MD, MMSc

9:15-9:25

**Questions**  
Panel

9:30-10:00

**Break/Exhibits**

**10:00-11:25**

**Classical Heme**

10:00-10:25

**Classical Heme**  
Valery Kogler, MD

10:25-11:10

**Treatment of Concomitant Arterial and Venous Thrombosis**

Stephan Moll, MD

11:10-11:25

**Questions**  
Panel

11:30-11:55

**Clinical trials**

Alana Ferrari, PharmD  
Cameron Lee, PharmD

11:55-12:40

**Lunch/Exhibits**

**12:40 PM-2:25**  
**Acute Leukemia**

12:40-1:05

**Updates in Acute Myeloid Leukemia**

Michael Keng, MD

1:05-1:30

**Advances in Frontline Management of B-cell Acute Lymphoblastic Leukemia**

Firas El Chaer, MD, MSHCM

1:30-2:15

**Clonal hematopoiesis of indeterminate potential (CHIP): Origins and clinical implications**

David Steensma, MD

2:15-2:25

**Questions**  
Panel

**2:25-3:45**  
**Plasma Cell**

2:25-3:10

**Advances in Multiple Myeloma and Other Plasma Cell Disorders in 2025**

Carlyn Tan, MD

3:10-3:35

**Pulmonary Complications of Stem Cell Transplant**  
Jeffrey Sturek, MD, PhD

3:35-3:45

**Questions**  
Panel

3:45-3:50

**Conference Summary/ Evaluations**

Firas El Chaer, MD

## Program Overview

This program will explore research and advances in the diagnosis and management of benign hematologic conditions and hematologic malignancies, including indications for novel therapies. Case-based presentations will highlight recommendations for treatment of common hematologic diagnoses.

## Educational Outcomes

- Define the new Acute Myeloid Leukemia (AML) classifications and discuss updated guidelines.
- Discuss the new treatment modalities for Myelodysplastic Syndromes (MDS).
- Explain the pathogenesis of Clonal Hematopoiesis of Indeterminate Potential (CHIP), identify its clinical implications and associated risks, and discuss current management strategies and future research directions.
- Describe current practices and innovations in transfusion medicine.
- Identify diagnostic and therapeutic strategies in multiple myeloma.
- Analyze pulmonary complications in hematologic diseases.
- Examine current and emerging therapies in lymphoma treatment.
- Discuss treatment strategies for concomitant arterial and venous thrombosis.

## Target Audience

Community hematologists and oncologists, as well as advanced practice providers, nurses, and pharmacists are welcome to attend.

## Course Directors


### Firas El Chaer, MD

Associate Professor of Medicine;  
Medical Director of Chronic & Acute  
Leukemia,  
MDS & MPN Clinical Research Team

### Hillary Maitland, MD, MS


Associate Professor of Medicine

## Invited Guest Faculty



### Matthew Davids, MD, MMSc

Director of Clinical  
Research,  
Dana-Farber Cancer  
Institute



### Stephan Moll, MD

Professor of Medicine,  
Division of Hematology,  
University of North  
Carolina  
School of Medicine



### David P. Steensma, MD, FACP

Chief Medical Officer  
Ajax Therapeutics,  
Cambridge MA



### Carlyn Tan, MD

Assistant Attending  
Memorial Sloan  
Kettering Cancer  
Center

## UVA Faculty

\* Indicates Planning Committee

### Rachel Chai, PA\*

Physician Assistant, Infusion Center

### Gina DeGenarro, DNP, RN, CNS, AOCN\*

Associate Professor of Nursing

### Alana Ferrari, PharmD, BCOP\*

Clinical Pharmacist, Hematology/  
Oncology

### Caroline Jones, PharmD\*

Pharmacist, Clinical Services

### Michael Keng, MD

Associate Professor of Medicine

### Valery Kogler, MD

Associate Medical Director of  
Cytotherapy & Cellular Apheresis,  
Transfusion Medicine / Blood Bank  
Services, Department of Pathology  
& Laboratory Medicine

### Cameron R. Lee, PharmD

Pharmacist, Investigational Drug  
Services

### Nathan Roberts, MD

Assistant Professor of Medicine

### Krithika Shanmugasundaram, MD\*

Assistant Professor of Medicine

### Jeffrey M. Sturek, MD, PhD

Assistant Professor, Pulmonary  
& Critical Care

### Tanya Thomas, DNP, APRN, AGCNS-BC, OCN\*

Clinical Nurse Specialist; Oncology and  
Hazardous Medication Safety

## Accreditation

In support of improving patient care, UVA Health Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

UVA Health Continuing Education designates this live activity for a maximum of **6.00 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

UVA Health Continuing Education awards up to **6.00 contact hour(s)** for nurses who participate in this educational activity and complete the post activity evaluation.

UVA Health Continuing Education awards 6.00 hours of participation to a participant who successfully completes this educational activity. UVA Health Continuing Education maintains a record of participation for six (6) years.

Credit will be uploaded to CPE Monitor within 60 days of the end date of the activity. A certificate from our learning portal validates only learner participation. It will be the responsibility of the pharmacist or pharmacy technician to provide the correct information in order to receive credit for participating in this CE activity. Please log into your NABP Profile to see your credit recorded and print your official transcript.

UVA Health Continuing Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.



This activity is designated for **6.00 AAPA Category 1 CME credits**. PAs should only claim credit commensurate with the extent of their participation. The University of Virginia School of Medicine and School of Nursing has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.

This activity is designated for **6.00 AAPA Category 1 Self-Assessment CME credits**. PAs should only claim credit commensurate with the extent of their participation.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **6.00 MOC points** in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

## Registration and Fees

Registration and payment are available at the [UVA Continuing Medical Education portal](#). Registration will close midnight on Monday April 1, 2025.

**NO WALK IN REGISTRATION.**

Syllabus will be available online the week of the conference until 30 days after the program. \*See cancellation policy prior to registration.

	Early Bird Discount (before 2/18/25)	After 2/18/25
Physicians	\$150	\$200
Other Healthcare Professionals	\$50	\$75

Please Note: Policies on cancellation, payment methods and accommodation requests can be found on our website under FAQs. Additional questions, please contact [uvacme@virginia.edu](mailto:uvacme@virginia.edu) or 434-924-5310.

## Contact Information

**Kara Watts**  
CE Program Manager,  
Office of Continuing Medical  
Education

[kt7r@uvahealth.org](mailto:kt7r@uvahealth.org)

434-409-0754